Your browser doesn't support javascript.
loading
Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM).
Bayle, A; Peyraud, F; Belcaid, L; Brunet, M; Aldea, M; Clodion, R; Dubos, P; Vasseur, D; Nicotra, C; Geraud, A; Sakkal, M; Cerbone, L; Blanc-Durand, F; Mosele, F; Martin Romano, P; Ngo Camus, M; Soubeyran, I; Khalifa, E; Alame, M; Blouin, L; Dinart, D; Bellera, C; Hollebecque, A; Ponce, S; Loriot, Y; Besse, B; Lacroix, L; Rouleau, E; Barlesi, F; Andre, F; Italiano, A.
Afiliación
  • Bayle A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Oncostat U1018, Inserm, Paris-Saclay University, labeled Ligue Contre le Cancer, Villejuif.
  • Peyraud F; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux; University of Bordeaux, Bordeaux, France.
  • Belcaid L; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Oncology, Rigshospitalet, The University of Copenhagen, Copenhagen, Denmark.
  • Brunet M; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Aldea M; Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Clodion R; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Dubos P; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Vasseur D; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Nicotra C; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Geraud A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Sakkal M; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Cerbone L; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Blanc-Durand F; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Mosele F; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Martin Romano P; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Ngo Camus M; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Soubeyran I; Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Khalifa E; Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Alame M; Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Blouin L; Department of Medical Biology and Pathology, Institut Bergonié Comprehensive Cancer Centre, Bordeaux.
  • Dinart D; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, Bordeaux; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux.
  • Bellera C; University of Bordeaux, Inserm, Bordeaux Population Health Research Center, Epicene Team, Bordeaux; Inserm CIC1401, Clinical and Epidemiological Research Unit, Institut Bergonié, Comprehensive Cancer Center, Bordeaux.
  • Hollebecque A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Ponce S; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Loriot Y; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France.
  • Besse B; Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Lacroix L; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Rouleau E; Department of Medical Biology and Pathology, Gustave Roussy, Villejuif.
  • Barlesi F; Department of Cancer Medicine, Gustave Roussy, Villejuif; Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France.
  • Andre F; Université Paris-Saclay, Université Paris-Sud, Faculté de médecine, Le Kremlin-Bicêtre, Paris; Department of Cancer Medicine, Gustave Roussy, Villejuif.
  • Italiano A; Drug Development Department (DITEP) Gustave Roussy - Cancer Campus, Villejuif, France; Department of Early Phase Trial Unit, Institut Bergonié Comprehensive Cancer Centre, Bordeaux; University of Bordeaux, Bordeaux, France. Electronic address: Antoine.italiano@gustaveroussy.fr.
Ann Oncol ; 33(12): 1328-1331, 2022 12.
Article en En | MEDLINE | ID: mdl-36122799
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicina de Precisión / Neoplasias Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: Ann Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article